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Summary
A double-blind, random ised study was conducted  to com pare the efficacy and safety o f  a com bination 
of pefloxacin and m etronidazole versus doxycycline and m etronidazole in patients with pelvic inflam m a­
tory disease (PID). The clinical diagnosis had to be confirmed by laparoscopy before patients were includ­
ed. O f the 74 patients who fulfilled the clinical criteria for PID , laparoscopy confirmed the diagnosis in 
only 40 patients (54%). The m icroorganism  most frequently found as causative pathogen was Chlamydia 
trachomatis. Both treatm ent groups showed a good response to the study-medication. At discharge 9 
patients in the pefloxacin group (45%) were cured and 10 patients (50%) had improved. In the doxycycline 
group 7 patients (35%) were cured and 10 patients (50%) had improved. Obviously pefloxacin/metroni­
dazole and doxycycline/metronidazole are equally effective in the treatm ent o f  PID.
Pelvic inflammatory disease; Antibiotics; Laparoscopy
ntroduction
M ost patients with pelvic inflam m atory disease 
PID) are treated on an epidemiological basis. The 
najor pathogens causing P ID  include Chlamydia 
rachomatis, Neisseriae gonorrhoeae, Mycoplasma 
jominis, Ureaplasma urealyticum, anaerobes (Pep- 
ococcus, Peptostreptococcus and Bacteroides)
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and aerobes (Streptococcus, Haemophilus influen­
zae and Escherichia coli) [1,2]. In the N etherlands, 
the recommended treatm ent regimen consists o f  
doxycycline combined with metronidazole. The 
Centers for Disease C ontro l recommend combined 
antimicrobial therapy for PID , including; (1) 
cefoxitin plus doxycycline or (2) clindamycin plus 
gentamicin [3].
Doxycycline is active against Gonococci, S trep­
tococci, C. trachomatis, M ycoplasm a, U rea ­
plasma, H. influenzae, E. coli as well as several 
anaerobes. However, doxycycline is not suitable 
for use as m onotherapy  because, o f  the anaerobes,
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only the Bacteroides species are sensitive to doxy­
cycline. As metronidazole is especially active 
against anaerobes, the com bination o f  doxycycline 
and metronidazole is thought to cover all the 
possible etiologic agents involved in PID. The 
tetracycline-resistant gonococci, however, have 
proved to be an increasing problem in the m anage­
ment o f  P ID  [4].
One o f the therapeutic goals in the m anagem ent 
o f  PID  is prevention o f  the late sequelae, such as 
chronic pelvic pain (18%) [13,14], recurrent P ID  
(23%) [14], ectopic pregnancy (a seven- to tenfold 
risk increase) [14] and infertility. In a cohort study 
in Sweden W estrom [13] noted a direct re lation­
ship between the num ber o f  episodes o f  infection 
the infertility rate, which ranged from 11% for a 
single episode to more than 50% in women with 
three or more episodes.
Pefloxacin is a new broad-spectrum  antim icro­
bial agent that belongs to the fluor-quinolones. 
W hat is im portant as far as gynecological infec­
tions are concerned, pefloxacin is active against 
Gram-negative diplococci, C. trachomatis, Urea- 
plasma and M. hominis [5-8]. The favourable 
pharm acokinetic properties o f  pefloxacin consist 
o f  a long plasma elimination half-life (12  h), a low 
protein binding and a high tissue affinity, indepen­
dent o f  the route o f  adm inistration (intravenously 
or oral).
Because o f  the interesting microbiological and 
pharm acokinetic properties o f  the new quinolones 
such as pefloxacin, a double-blind clinical study 
was performed at the D epartm ents  o f  Gynecology 
of the Leiden University Medical Center and the 
municipal hospital ‘Leyenburg’ in The Hague. In 
this study we com pared the efficacy and safety o f  
a com bination o f  doxycycline and m etronidazole 
versus pefloxacin and metronidazole.
Laparoscopical studies have shown that the 
diagnosis o f  P ID  based on clinical criteria is often 
inaccurate [9-11], and that laparoscopy is a safe 
way to make an accurate diagnosis o f  P ID  and an 
excellent means to obtain representative cultures. 
It was for this reason that in this study the clinical 
diagnosis had to be confirmed by laparoscopy.
Patients and Methods
The design o f  this clinical trial was a doub le­
blind randomized com parative study. Patients 
were randomised using a com puter-generated 
table. The study was approved by the ethical com ­
mittees o f  both hospitals.
Population
To be eligible for the study, patients had to meet 
the strict criteria for the clinical diagnosis PID
[12], after having given informed consent. The 
diagnosis had to be confirmed by laparoscopy 
before the patients could enter the study. M inors 
under the age o f  16, pregnant or lactating women, 
and patients with two different infections, as defin­
ed by two sites infected by two different p a th o ­
gens, were excluded from the study.
Diagnosis
Laparoscopy was performed in all patients with 
the presumed diagnosis o f  PID. The criteria were: 
(A) hyperemia or edema o f  the tube; (B) exudate 
coming from the fimbrial end o f  the tube; (C) 
purulent exudate in the pelvis; and /o r (D) pelvic 
abscess.
Microbiology
Specimens were taken from the cervix, from the 
suspected infected sites (by laparoscopy), from a 
pelvic abscess (by aspiration o f  the abscess), from 
the urine, and from the blood (in the case of 
tem peratures >38.5°C). These samples were 
transported, stored and cultured according to 
routine procedures for aerobic and anaerobic  bac­
teria. S tandard  laboratory  techniques were used 
for isolation and identification o f  causative p a th o ­
gens. Specific investigations for C. trachomatis and 
for N. gonorrhoeae were performed. C. trachomatis 
was identified by culture, antigen detection and 
serology. F o r  transport and preservation o f  C. 
trachomatis we used a well tested transport- 
medium (phosphate buffered glycerol), a maxi­
mum transport time o f 2 h, and, if necessary, 
storage at 4°C for at most 48 h. H E L A  229 cells 
were used for culture. C. trachomatis was iden­
tified by antigen detection with m onoclonal an ti­
bodies. The antibody titers were defined as 
suspicious for C. trachomatis for IgG titers 
>  1:128, or a significant ( >  4-fold) increase in anti­
body concentration. Antibiotic susceptibility test­
ing was carried out by means o f  the standardized
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disc diffusion test according to the guidelines of 
the W .R .G . (W erkgroep Richtlijnen 
Gevoeligheidsbepalingen, this is the D utch study 
group which draws up guidelines for susceptibility 
tests). In the case o f  pefloxacin 10 /xg discs were 
used. Strains were considered susceptible to 
pefloxacin if M IC  was <  1 /xg/ml, intermediate if 
the M IC  was 2 - 4  ¿ig/ml and resistant if the M IC  
was > 8  ¿¿g/ml. These values corresponded with 
breakpoints in the diffusion test o f  20 mm and 14 
mm, respectively.
Treatment
The study medication in one regimen consisted 
of pefloxacin 800 mg/day. In the o ther regimen 
doxycycline was administered in an initial dose o f  
200 mg, followed by 100 mg daily. In both 
regimens m etronidazole was added, in the form of 
500 mg every 8 h. The route o f  adm inistra tion  (i.v. 
or oral) depended on the condition o f  the patients, 
using the physical findings and the body tem pera­
ture as parameters.
Treatm ent allocation was perform ed as soon as 
specimens were sampled and stored under suitable 
conditions. At the end o f therapy or upon dis­
charge sampling was repeated. D ura tion  o f  trea t­
ment was at least 10 days, and maximal 14 days, 
unless the clinical response was considered insuffi­
cient after 5 days. The minimal dura tion  o f  the ra ­
py to allow efficacy assessment was 5 days.
Evaluation
The clinical outcom e was defined and rated as 
follows:
•  Cure: durable apyrexia and resolution o f  all 
clinical symptoms.
•  Improvement: am elioration o f  signs and 
symptoms w ithout complete cure.
•  Failure: lack o f  favorable clinical response 
or deterioration o f  clinical condition.
•  Relapse: reccurrence o f  clinical symptom s 
after cessation o f  therapy.
The clinical condition was evaluated daily. 
Tlinical response was evaluated after 3 and 5 days 
)f therapy, and at discharge or on cessation o f  
reatment. A final clinical exam ination took place 
between day 7 and day 15 after drug d iscontinua­
tion (earlier in case o f  early clinical relapse). Pa­
tients who had not undergone this post-treatm ent 
follow-up were not considered suitable for efficacy 
assessment.
If  clinically indicated, patients were eligible for 
second-look laparoscopy after 3 - 6  m onths, to 
assess the late sequelae o f  the P ID  and the trea t­
ment. The findings were registered according to 
Siegler [14].
Safety
All patients who received at least one dose o f  the 
study medication were analysed for safety o f  thera­
py. Any clinical adverse reaction observed during 
the study period was reported, as well as the sever­
ity, the relationship to the study m edication (in the 
investigators’ opinion) and the outcome.
Standard  laboratory  tests were performed 
before therapy initiation, after 5 days o f  therapy 
and at the end o f  therapy.
Statistics
The chi-square test was used to com pare the 
efficacy and the safety o f  the two treatm ent 
regimens.
Results
Patient characteristics
Between August 1987 and December 1990, 74 
patients fulfilled the clinical criteria for PID . H ow ­
ever, laparoscopy confirmed the diagnosis in only 
40 o f those patients (54%) (Table I). O f  the 40 p a ­
tients with a laparoscopically diagnosed PID , 27 
were diagnosed and treated at the University H os­
pital Leiden, 13 were diagnosed and  treated at the 
municipal hospital ‘Leyenburg’ in The Hague. The 
study groups consisted o f  40 patients, 20 o f  whom  
received pefloxacin and m etronidazole, and 20 
doxycycline and metronidazole. Both study groups 
were distributed equally over the two hospitals.
The two study groups did not differ significantly 
with regard to dem ographic data , gynecological 
history, contraceptive use or sexual activity. N o r  
were there any significant differences between 
both groups in presenting symptom s and laparo ­
scopic findings. Table I shows the laparoscopic 
findings, Table II the clinical findings and labo ra ­
tory results.
TABLE I
t
#
Laparoscopic findings in 74 patients with the presumed diagno­
sis PID
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n = 14
PID 40 (54%)
— Hyperemia or edema of the tube 39 (98%)
— Exudate coming from the fimbrial
end of the tube 20 (50%)
— Purulent exudate in the pelvis 16 (40%)
— Pelvic abscess 4 (10%)
No pathology 22 (30%)
Other pathology 12 (16%)
— Appendicitis 6 (50%)
— Ovarian cyst 3 (25%)
(Bleeding: 1)
(Rupture : 2)
— Subserous myoma (torsion) 1 (8.3%)
— Ectopic pregnancy 1 (8.3%)
— Diverticulitis 1 (8.3%)
Microbiological features 
The microorganism most frequently found as 
causative pathogen was C. trachomatis (see Table 
IV for causative pathogens).
The susceptibility data  showed that the E. coli 
isolated had a better susceptibility in vitro for
TABLE II
Clinical findings and laboratory results in 40 laparoscopically 
confirmed PID patients
Pefioxacin/ Doxycycline/ 
metronidazole metronidazole
n = 20 n = 20
Body temperature >38°C 11 (55%) 8 (40%)
Presence of an inflammatory
mass noted on pelvic 4 (20%) 2 ( 10%)
examination or sonography
Leucocytosis >  10 000
WBC/mm3 14 (70%) 12 (60%)
ESR >  25 mm 12 (60%) 15 (75%)
Gramstain suggesting
N. gonorrhoeae 0 (0%) 0 (0%)
Pelvic tenderness 20 ( 100%) 20 ( 100%)
Pelvic induration 9 (45%) 7 (35%)
pefioxacin than for doxycycline. In one patient the 
E. coli was resistant to doxycycline, the antibiotic 
regimen this patient was treated with.
At discharge no microorganisms were cultured 
on the examination sites.
Clinical response
Both groups showed a good response to the 
study medication (Table III). In the cases where 
treatm ent failed, surgical intervention was 
necessary. The differences in treatm ent results 
were not significant.
The body tem perature in both groups dropped 
to levels o f  37.0°C or lower. The ESR decreased to
14 (median) in the pefioxacin group and to 20 (me­
dian) in the doxycycline group.
The physical findings in both groups improved 
after treatment. The differences between the two 
treatm ent groups were not significant. This also 
applied to the subjective painscore: in the pefiox­
acin group 11 patients had no pain and 9 patients 
had minimal pelvic pain after treatment. In the 
doxycycline group there were 16 patients w ithout 
pain and 4 patients with minimal pain after 
treatment.
TABLE III
Found pathogens in 40 laparoscopically confirmed PID pa­
tients
Pefioxacin/ Doxycycline/ 
metronidazole metronidazole 
n = 20 n = 20
C. trachomatis 11 10
— C. trachomatis alone 5 4
— C. trachomatis
combined with:
+ G. vaginalis 1 2
+ Anaerobes 2 —
+ E. coli 1 —
+ Streptococcus 1 —
+ Mixed flora 1 2
+ 5. aureus — 1
+ N. gonorrhoea — 1
N. gonorrhoea 1 —
Anaerobes — 1
E. coli — 2
G. vaginalis — 3
Mixed flora 1 2
No microorganisms isolated 7 2
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TABLE IV
Results of treatment
Pefloxacin/ 
metronidazole 
n = 20
Doxycycline/ 
metronidazole 
n — 20
Day 3
— Cured 0 (0%) 0 (0%)
— Improved 18 (90%) 17 (85%)
— No change 2 ( 10%) 3 ( 15%)
Day 5
— Cured 1 (5%) 0 (0%)
— Improved 17 (85%) 19 (95%)
— No change 2 ( 10%) 1 (5%)
At discharge
— Cured 9 (45%) 7 (35%)
— Improved 10 (50%) 10 (50%)
— No change 1 (5%) 3 ( 15%)
No significant differences (chi-square test).
In 10 patients o f  the pefloxacin group and in 11 
patients o f  the doxycycline group a second-look 
laparoscopy was carried out. The indication for 
these second-look laparoscopies was (future) child 
wish. In the pefloxacin group no abnorm alities 
were found in 7 patients, adnexal adhesions in 2 
patients and tubal occlusion in 1 patient. In the 
doxycycline group no abnorm alities were found in 
7 patients, adnexal adhesions in 3 patients and 
tubal occlusion in 1 patient. In neither group was 
any case o f  persistant inflam m ation found.
Side-effects
In the pefloxacin group 1 patient had a side- 
effect (nausea) w ithout any consequences for the 
projected therapy. In the doxycycline group 2 p a ­
tients had side-effects requiring d iscontinuation  of 
the study medication. These two side effects con ­
sisted of vomiting and a pruritic rash.
Comment
The classical com bination  o f  clinical symptoms 
and signs for P ID  was confirmed by laparoscopy 
in only 54% o f  the cases. This finding confirms the 
assumption that the clinical pattern  o f  P ID  is un ­
characteristic, and similar to that o f  other
pathology. The use o f  laparoscopy for the d iagno­
sis P ID  is, therefore, o f  great im portance [15].
To preserve fertility and to prevent the sequelae 
o f  PID, treatm ent regimens should be instituted 
that are based on a knowledge o f  the 
microorganisms involved in PID . The initial step is 
to obtain specimens for microbiologic evaluation 
directly from the source o f  infection —  the fallo­
pian tubes —  by means o f  laparoscopy.
To identify a C. trachomatis infection, the cul­
ture is still the most reliable technique. However, 
the isolation rates may be falsely low because C. 
trachomatis is an obligate intracellular pathogen 
that may not survive long in the exudate. 
Therefore, in this study we used culture, antigen 
detection and serology to determine a C. 
trachomatis infection.
In many western societies, the most com m on 
cause o f  sexually transm itted diseases is no longer 
N. gonorrhoeae but C. trachomatis [16], which was 
also the case in our study. The prevalence o f  N. 
gonorrhoeae and C. trachomatis infections seems to 
vary greatly, depending on the population  studied. 
The literature [17,18] shows a higher prevalence o f  
N. gonorrhoeae than we found in our study.
The two antibiotic regimens both  dem onstrated  
good efficacy in the therapy o f  patients with 
laparoscopically proven PID. However, our study 
showed that in vitro the susceptibility o f  E. coli 
was better for pefloxacin than  for doxycycline. 
A lthough our study did not show a significant ad ­
vantage in favour o f  pefloxacin, the E. coli suscep­
tibility for doxycycline in com bination  with the 
increasing problem  o f  tetracycline-resistant 
gonococci in the m anagem ent o f  PID , supports  the 
use o f  pefloxacin with m etronidazole as an ap p ro ­
priate therapy for PID.
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